ENSG vs SYRE
Ensign Group vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
| Metric | ENSG | SYRE |
|---|
| AI Score |
69
|
67
|
| Price |
$180.10
|
$102.72
|
| P/E Ratio |
27.43×
|
-52.69×
|
| ROE |
15.4%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
14.1%
|
0.0%
|
| Debt / Equity |
0.92×
|
0.00×
|
| Dividend Yield |
0.1%
|
0.0%
|
| RSI (14) |
71.8
|
53.3
|
| Beta |
0.694
|
3.026
|
| Expected Upside |
+5.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ENSG versus SYRE.
ENSG leads by 2 points.
ENSG scores 69/100 (Buy) versus SYRE at 67/100 (Insufficient Data).
ENSG Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
SYRE Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical